Background Mutations that disrupt the open reading frame and prevent full translation of DMD, the gene that encodes dystrophin, underlie the fatal X-linked disease Duchenne muscular dystrophy. Oligonucleotides targeted to splicing elements (splice switching oligonucleotides) in DMD pre-mRNA can lead to exon skipping, restoration of the open reading frame, and the production of functional dystrophin in vitro and in vivo, which could benefi t patients with this disorder.
Introduction
Duchenne muscular dystrophy (DMD) aff ects 1 in 3500 newborn boys, causing eventually progressive muscle weakness, cardiomyopathy, and respiratory failure. Patients are diagnosed when they are toddlers, become wheelchair-dependent in their early teens, and die in their 20s. With improvements in standards of care, including non-invasive ventilation and glucocorticoid and cardio protective treatment, many individuals with DMD survive beyond their mid-20s 1,2 despite having severe and disabling weaknesses.
DMD is caused by the absence of the protein dystrophin. Dystrophin associates with other sarcolemmal proteins of the dystrophin glycoprotein complex and connects the cytoskeleton to the extracellular matrix. The absence of dystrophin reduces the stability of the sarcolemma and increases intracellular calcium infl ux, which is followed by degeneration of the muscle fi bres. Dystrophin is encoded by DMD. Deletions (in about 65% of patients), duplications (in about 10% of patients), point mutations (in about 10% of patients), or other smaller rearrangements can disrupt the open reading frame of DMD, leading to premature termination of its translation, 3, 4 whereas deletions or duplications that maintain the open reading frame can lead to truncated but functional dystrophin, which underlies the milder disorder Becker muscular dystrophy (BMD). 5 The spectrum of severity for BMD varies, ranging from diffi culties in walking in the late teens to preserved walking ability into late adulthood and a normal lifespan. 6 Up to 50% of patients with DMD have sporadic dystrophin-positive revertant fi bres. 7 This dystrophin expression arises from alternative processing of DMD pre-mRNA that skips some exons, leading to restoration of the open reading frame. 8 Revertant dystrophin is correctly localised to the sarcolemma and mediates the assembly of other proteins of the dystrophin glycoprotein complex, suggesting that it is physiologically functional. The occurrence of revertant fi bres and the mild symptoms of some individuals with BMD with in-frame deletions suggest that it might be feasible to modify the splicing of the DMD transcript and, by skipping the mutated exons, produce functional dystrophin (fi gure 1).
Some exon deletions are more common than others.
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Deletions of exons 50, 52, 52-63, 45-50, 47-50, and 49-50 cumulatively account for 13% of all the deletions in DMD. 12 Skipping of exon 51 in patients with these deletions should restore the open reading frame of DMD and lead to the expression of functional dystrophin.
Antisense oligonucleotides have been used for experimental gene silencing and recently as spliceswitching oligonucleotides to modify splicing and induce exon skipping, 13 particularly in myoblasts from patients with DMD in vitro, 14, 15 and in mouse and dog models of DMD. [16] [17] [18] One patient with DMD who had a deletion of exon 20 received an intravenous infusion of a splice-switching oligonucleotide with a phosphorothioate backbone, which induced skipping of exon 19 and restored the DMD open reading frame in lymphocytes but had no eff ect in skeletal muscle. 19 A recent phase 1 clinical study reported encouraging results in four boys with DMD who received a single intramuscular injection of a 2ĽO-methyl-ribooligonucleoside-phoshophorothioate splice-switching oligonucleotide that was targeted to skip exon 51. This treatment led to appreciable expression of dystrophin and was well tolerated. 20 Other chemically modifi ed oligonucleotides have been used in preclinical models and clinical trials. Phosphorodiamidate morpholino oligomers (PMOs; fi gure 1) are non-toxic, and in the mdx mouse model of DMD they were the most eff ective oligomer chemistry for inducing exon skipping and restoring long-lasting (weeks) dystrophin expression after intravenous or intramuscular injection. [21] [22] [23] [24] PMOs, unlike other antisense oligonucleotides, are uncharged, not metabolised, and in preclinical or clinical studies were not associated with activation of the immune system, anaphylaxis, hypotension, or anti-arrhythmias. 25 On the basis of these data, we have studied the safety and biochemical effi cacy of AVI-4658, a PMO designed to target exon 51 that is delivered by intramuscular injection. Here, we report the results of a single-blind, placebo-controlled, dose-escalation safety and effi cacy study of PMOs in patients with DMD.
Methods

Patients
This single-site, non-randomised, single-blind (investigator) study was done at Imperial College NHS Trust, London, UK, in patients with DMD who were recruited nationally. Participants were boys with a classic clinical diagnosis of DMD 26 who were aged between 10 and 17 years inclusive when the study drug was given. All participants had a deletion that can be rescued by the skipping of exon 51 (eg, deletion of exons 45-50, 47-50, 48-50, 49-50, 50; 52, or 52-63); had fewer than 5% revertant fi bres seen in a muscle biopsy; had the extensor digitorum brevis (EDB) muscle suffi ciently preserved (grade 1 to 3: grade 1 is near normal; grade 2 is 30-60% of the muscle is normal; and grade 3 is muscle is almost all abnormal but some normal muscle still present at the periphery), as determined by MRI of the feet; 27,28 had a forced vital capacity of 25% or more and a normal overnight sleep study before 3 months from the day of injection; were able to comply with all study assessments and return for all study visits; and had adequate psychiatric adjustments, supportive psychosocial circumstances, and full understanding of the study aims, process, and likely outcomes. Exclusion criteria were: absence of EDB muscles or advanced pathology of EDB muscles (grade 4) on muscle MRI; left ventricular shortening fraction of 25% or less, an ejection fraction of less than 35% seen by echocardiography within 3 months of visit one, or both; respiratory insuffi ciency defi ned by the need for invasive or non-invasive ventilation; severe cognitive dysfunction that meant the patient was unable to understand and collaborate with the study protocol; immune defi ciency or autoimmune disease; bleeding disorders or chronic anticoagulant treatment within 3 months before study entry; medication with anabolic steroids, creatine protein supplementation, albuterol, or other beta agonists, and intranasal, inhaled, or topical steroids for a disorder other than muscular dystrophy within 1 week before study entry; surgery within 3 months before study entry or planned for anytime during the study; inability to undergo MRI (eg, owing to metal implants); known allergies to products likely to be used in the study (eg, antiseptics or anaesthetics); and participation in another experimental study within 4 weeks of study entry.
Standard-of-care treatment, including glucocorticoids and cardioprotective drugs, was continued in all patients. All study participants were informed before enrolment of the procedures, risks, and possibility of no benefi t. All participants provided written assent, and their parents gave written informed consent before enrolment in this study. This trial was designed and done in compliance with UK good clinical practice, International Conference on Harmonisation (ICH) E6, and all applicable regulatory requirements were met (UK Medicines and Healthcare Products Regulatory Agency, UK Gene Therapy Advisory Committee, and local research ethics committees).
Trial activities and adverse events were monitored by a safety monitoring committee. The safety monitoring committee met on the following occasions: before recruitment of the fi rst patient; to authorise the recruitment of the second patient after the fi rst patient was biopsied; and after the second patient was studied but before recruitment of the fi rst patient in the high-dose cohort without use of an intermediate dose (0·27 mg). The safety monitoring committee also met to discuss and authorise a proposed change to the protocol, which enabled us to increase the dose directly to the higher dose, to authorise the recruitment of the last two patients in the high-dose cohort, and to discuss a severe adverse event (bilateral surgical wound infection after the muscle biopsies) in one of the patients in the second cohort.
The protocol was also amended in May, 2008, so that we did not need to recruit the third and last patient into the low-dose group (0·09 mg) or recruit the three patients into the intermediate dose group (0·27 mg), and permitted us to recruit patients in the high-dose group (0·9 mg). Because we had identifi ed considerable comorbidity that precluded recruitment of some of the older patients, we also requested and obtained permission to lower the age at inclusion to 10 years and to be able to recruit ambulant patients.
Procedures
To confi rm that each patient had less than 5% dystrophin-positive revertant fi bres, each of the original muscle biopsies used to diagnose the patients was re-evaluated (table 1) . 29 Presence of a deletion suitable for exon 51 skipping and no additional mutations were reconfi rmed by sequencing of all the intact DMD coding exons and their intron-exon boundaries in all patients. The extensor digitorum brevis (EDB) muscle at the back of the foot was selected as the target muscle. This muscle is well preserved in non-ambulant boys with DMD (Kinali and Muntoni, unpublished), is, for the most part, functionally redundant (an important consideration in a study that is not expected to lead to functional benefi t), and can even be absent in some individuals. 30 MRI confi rmed the presence and preservation of the EDB muscles in all patients 31, 32 and that involvement of the EDB muscle was not more than grade 3.
27,28 Healthy muscle biopsies were obtained from the Dubowitz Neuromuscular Centre biobank.
Psychiatric assessments were done to ascertain the expectations and risk of reactive depression for each patient and their family by docu menting previous and current psychiatric adjustment and current psychosocial stresses and supports. Parents and children were interviewed separately. The parental questionnaire included the Strengths and Diffi culties Questionnaire, the Parental Stress and Support Questionnaire, the General Health Questionnaire, and the Family Assessment Device, which are all validated assessment tools. [33] [34] [35] [36] Patient interviews with the psychiatrist focused on their understanding of the trial, their general adjustment at home and school, emotional and depressive symptoms, and the Strengths and Diffi culties Questionnaire and the Hamilton Anxiety and Depressive Scale. 34, 37 Cultured fi broblasts from a skin biopsy were analysed to verify oligonucleotide-induced splice switching of exon 51 in all patients. Fibroblasts were forced into myogenic diff erentiation by transduction with an adenovirus expressing the myogenic regulatory factor protein MyoD, 38 and cultures were transfected with AVI-4658 congener on a 2ĽO-methyl backbone (300 nM) with Lipofectin (Invitrogen, UK). 39 RNA was isolated 48 h after transfection and analysed after reverse transcriptase-polymerase chain reaction (RT-PCR) amplifi cation. 39 7 days after transfection, cells were harvested for western blot analysis, 39 and lysates were probed with Dys1 (Vector Laboratories, UK), an anti-dystrophin monoclonal antibody. Dysferlin (Vector Laboratories, UK) was used as a loading control. Baseline safety blood analyses, including tests for anti-dystrophin antibodies 40 and T-cell subsets (CD4: CD8), were also done.
AVI-4658 is an exon 51-targeted PMO (sequence CTCC AACATCAAGGAAGATGGCATTTCTAG). 39 AVI-4658 was synthesised and purifi ed by AVI BioPharma (Portland, OR, USA) and was supplied as a low endotoxin and low bioburden powder, which was reconstituted in normal saline in the operating theatre.
This dose escalation intramuscular trial was done in seven patients, who received either of two doses: two patients received 0·09 mg and fi ve patients received 0·9 mg of AVI-4658; both doses were diluted in 900 μL normal saline (0·9%) and were injected in one EDB muscle; the contralateral EDB muscle was injected with 900 μL normal saline. The dose was divided into nine 100 μL injections in the fi rst fi ve patients and four 225 μL injections in the last two patients; this regimen reduced leakage into the skin, which was seen to some extent in patients 1-4. To ensure delivery in the muscle, the drug was injected with a 22 gauge EMG delivery needle (Pajunk, Multistim Sensor, Germany) inside a 1 cm² grid drawn in non-permanent ink on the skin over the site of the EDB muscles. The site and depth of the injections were recorded on videotape. After each injection, the needle was manipulated to confi rm its correct placement within the muscle. This took about 1 min. Each infusion was completed in about 30 s. After infusion, the needle was left in place for about 30 s to avoid leakage. The choice of which muscle to inject with the PMO or saline was made in the operating theatre on the day of the injection and the person who made the decision (FM) was masked to whether the patient was right-handed or left-handed. Patients and investigators (except MK, SC, and FM) were masked to which site received the active compound. The procedure was done under general anaesthetic in six patients; one patient opted to have the treatment under local anaesthetic. Both types of anaesthesia were available, and the choice was left to the families.
For all patients, an open biopsy of both EDB muscles was done between 3 and 4 weeks after injection. The rationale for this time frame was taken from previous work in mice and in humans. 17, 20 In the mdx mouse, the same level of dystrophin expression was detected at 4 weeks as was detected at 2 weeks after an intramuscular injection of a 2Ľ O-methyl antisense oligonucleotide designed to skip dystrophin exon 23. 17 Also, in a study of intramuscular injection of a 2Ľ O-methyl antisense oligonucleotide that targeted exon 51, given to patients with DMD, the skipped products and dystrophin were still detected in muscles that were analysed 4 weeks after intramuscular injection. 20 The area immediately below the needle track was exposed and an open biopsy was taken and rapidly frozen in liquid nitrogen-cooled isopentane, according to standard techniques. 29 To ensure that all the injection site had been obtained, most of the EDB muscle was removed.
Safety was determined by physical examination and haematological and urinary parameters, which were assessed periodically. The injection sites were monitored for local reaction and reactive pain. Patients were followed-up at timed intervals for 120 days after treatment. Any immune response against the newly synthesised dystrophin was assessed by the production of anti-dystrophin antibodies: serum samples were used to probe western blots loaded with lysates of muscle from the AD17 transgenic mouse, which overexpresses full-length human dystrophin; goat anti-human-IgG was used as the secondary antibody (Bio-Rad, UK). 40 The presence of T cells and B cells in each biopsy was ascertained by immunohistochemistry with antibodies raised against human CD3, CD4, CD8, or CD20 (Dako, UK).
RNA extraction and RT-PCR analysis were done on ten serial 7 μm sections of the frozen muscle sample. 39 Direct DNA sequencing of the excised bands was done by University College London Scientifi c Support Services. For western blotting, proteins from 20 serial 10 μm sections of muscle were isolated directly in 50 μL of loading buff er and analysed as previously described. 39 For immunohistochemical detection, 29 unfi xed, frozen serial sections (7 μm) were incubated for 1 h with monoclonal antibodies against dystrophin (Dys 2 [exon 77-79]; Vector Laboratories, UK), MANDYS106 41 (exon 43; a gift from G Morris, Oswestry, and the MDA Monoclonal Antibody Resource), and β-spectrin (Vector Laboratories, UK) 29 and were then assessed by two investigators (LF and CS) who were masked to the identity of the patient and which side received the active compound. Images were captured with a Leica DMR microscope linked to MetaMorph, version 7.5 (Molecular Devices, CA, USA). Quantitative studies were done as follows: the numbers of dystrophin-positive and dystrophin-negative fi bres in the muscle fascicles adjacent to a presumed injection site were counted on the MANDYS106-stained sections of AVI-4658-treated muscles and areas of control muscles chosen at random by two independent investigators (JM and CA). Dystrophin expression was evaluated in 40 muscle fi bres selected at random on one representative transverse MANDYS 106-stained region per biopsy. Expression was normalised against the expression of β-spectrin on serial sections and was compared with sections of normal control muscle and the contralateral EDB saline-injected biopsy that were processed in the same way and simultaneously labelled with the same antibodies. Four fi elds of the immunostained transverse cryosection of each muscle were selected at random (out of focus) and these areas (in focus) were photographed. Ten regions per image, each including an area of membrane and fi bre cytoplasm, were selected by moving the cursor across the image and were analysed with MetaMorph. We measured the relative intensity of dystrophin in 100 dystrophinpositive and 100 dystrophin-negative fi bres in the same regions of a section of treated muscle from each patient. This trial is registered, number NCT00159250.
Role of the funding source
The study was funded by the UK Department of Health and sponsored by Imperial College London. Neither had a role in the study design, data collection, data analysis, data interpretation, or writing of the report. AVI Biopharma manufactured and supplied AVI-4658 for the study and provided preclinical testing, packaging, labelling and the investigator brochure for the drug. The company supported the toxicity studies and participated in the design of the protocol, the execution and monitoring of the study, and discussions with the regulatory authorities. All authors have seen and approved the submitted version of the manuscript.
Results
MRI confi rmed that the EDB muscles in all patients had changes that were less than grade 4 (fi gure 2). The diagnostic muscle biopsies were re-analysed with Dys1, Dys2, and Dys 3 antibodies to confi rm there was no or little dystrophin and less than 5% of the fi bres were Exon 47 Exon 52 revertant (table 1) . Treatment of MyoD transfected fi broblasts with the 2Ľ O-methyl congener of AVI-4658 showed exon skipping in the RT-PCR products (confi rmed by sequencing) and dystrophin expression on western blot in all patients (fi gure 2, webappendix). Four patients who had mild cardiac involvement were on treatment with angiotensin-converting enzyme (ACE) inhibitors before recruitment (table 2) . Patient psychiatric adjustment and family psychosocial circumstances were deemed to be adequate for all patients included in the study. One patient who was from a family with unrealistic expectations and psychiatric problems was excluded.
All safety assessments showed no adverse events that were related to AVI-4568. All patients showed some short-lived, bilateral, localised reactions in both EDB muscles after the injections and muscle biopsies (table 2) . In one patient, the echocardiogram at 3 months after the screening visit showed deterioration in fractional shortening, despite ACE inhibitors. This was attributed to the natural history of DMD, and the patient's condition stabilised on beta-blockers. One patient developed bilateral cellulitis in the feet after the muscle biopsies and needed intravenous antibiotics. A short period of refusal to bear weight resolved without consequences.
Light microscopy and immunocytochemistry done masked to treatment showed no diff erences in infl ammatory infi ltrates between the treated and control EDB muscles in all patients (table 2) . There was no induction of anti-dystrophin antibodies after treatment with the phosphorodiamidate morpholino oligomer, although two patients (patient one and patient six) had low levels of cross reactivity with dystrophin in their pretreatment and post-treatment serum samples (not shown).
Both patients who had the low dose AVI-4658 showed little expression of dystrophin, despite dystrophin being robustly restored in the cultured fi broblasts, ahead of the injection of the antisense AVI-4658. This suggests that there is a lower threshold eff ect, and the low dose did not seem to be suffi cient to induce exon skipping in patients with Duchenne muscular dystrophy; therefore, we proceeded straight to the high dose.
Biopsies of AVI-4658-injected EDB muscles and the contralateral saline-injected EDB muscles were analysed by assessors who were masked to which muscle was the treated one. This involved quantifi cation of immunostained, dystrophin-positive fi bres, the detection of exon 51 skipped RNA (table 1) , and immunoblot analysis. After immunostaining of muscle sections with anti-dystrophin antibodies (Dys2 and MANDYS106), all patients treated with high-dose AVI-4658 showed a strong dystrophin signal that prevented masking of which side was the treated one in all patients (fi gure 3). The results also showed variable low-level immunostaining of the saline-treated muscles in all patients, which underscores the importance of this control (webappendix). Sarcolemmal colocalisation of dystrophin with other proteins of the dystrophin glycoprotein complex (webappendix) suggested that dystrophin interacted with other members of this protein complex and was therefore presumed to be functional. However, in patients one and two, who received low-dose AVI-4658, there was no clear diff erence in protein expression between the treated and control EDB muscle biopsies (webappendix).
The results from the high-dose group were quantifi ed further by image analysis of fl uorescent sections stained with the MANDYS106 antibody, which has been used previously for this purpose. 20 Masked measurements of the fl uorescent intensity of dystrophin staining were done in 40 fi bres chosen at random per drug-treated and saline-treated muscle sample. In the high-dose group, the mean diff erence in measurements of the fl uorescent intensity of dystrophin expression in all treated muscles was about 17% (range 11-21%) more than that in the contralateral saline-injected muscles (one-sample paired t test p=0·002; fi gure 4). Because the random measurements took into account areas that contained both dystrophin-positive and dystrophin-negative fi bres for the intensity measurements, we targeted the dystrophin-positive fi bres within the same area. The intensity in these fi bres in patient 4 was 42% of that in healthy muscle (fi gure 4).
Counting of the positive fi bres stained with MANDYS106 was done after confi rmation of which muscle was the treated muscle and which was the control, owing to low-level staining in several of the patients (fi gures 3 and 4). If the low-level immunostaining was not factored in, the number of positive fi bres in the side that received AVI-4658 reached 100% in several patients. We therefore adjusted the detection threshold so that only the rare revertant fi bres were seen in the saline-injected muscle. This threshold was then subtracted from the contralateral AVI-4658 injected muscle. A mean of 419 fi bres (range 262-792 fi bres) were seen in the four areas counted from the treated muscles in patients from the high-dose group. In the fi ve muscles treated with high-dose AVI-4658 there was a mean of 269·8 (SD 204·5) dystrophin-positive fi bres by contrast with 6·6 (8·1) dystrophin-positive fi bres in the saline-treated side (one-sample paired t test p=0·02). When the proportion of positive fi bres in the fascicles that were assumed to relate to the needle track were counted, the number varied between 44% and 79% (mean 59·8% [SD 13·9]; table 3). At least 262 fi bres were counted in each sample. There was no correlation between the proportion of dystrophin-positive fi bres and the severity of fi brosis (table 1) . The results of the dystrophin immunostaining were corroborated by those from the RT-PCR and western blots, which were done masked to treatment. Exon 51 skipping and distinct bands of dystrophin protein were seen in the drug-treated muscles but not in the saline-treated muscles of patients in the high-dose group (fi gure 5). Exon 51 skipping was also seen in the two patients in the low-dose group, but this was less abundant and only detected when high-sensitivity conditions were used (additional cycles); 20 however, these two patients did not have detectable dystrophin on western blot (webappendix). Sequencing of the RT-PCR products confi rmed accurate skipping of exon 51 in the treated muscles of all patients (fi gure 5). Immunoblot analysis showed bands of the expected molecular weight in the AVI-4658-treated muscles.
Untreated Treated
Discussion
This single-blind study assessed the local safety and biochemical effi cacy of intramuscular injection of AVI-4658 in patients with DMD who have deletions that are responsive to skipping of DMD exon 51. We showed, in vivo, that the PMO AVI-4658 induced specifi c skipping of exon 51 and the production of dystrophin that was correctly localised at the sarcolemma. The treatment was not associated with any systemic or local adverse events or with any immune response against dystrophin.
Specifi c dose-dependent exon skipping was seen in the treated EDB muscles compared with the contralateral saline-injected muscles. Patients in the low-dose group showed RT-PCR evidence of exon skipping, confi rmed by sequencing, but no dystrophin protein was detected.
Strong expression of dystrophin was seen in the treated muscle in all patients in the high-dose cohort after subtraction of the signal intensity for the low-level of antibody labelling in the sarcolemma of the saline-injected contralateral muscle (fi gure 3). Localisation of dystrophin to the sarcolemma suggests appropriate interaction with other proteins of the dystrophin glycoprotein complex. Western blot analysis detected increased expression of dystrophin in the AVI-4658-treated muscle of all patients who received the high dose, and the immunoblot detected expression of dystrophin of the expected molecular weight in all patients. However, the quantifi cation of dystrophin from a western blot after an intramuscular injection is diffi cult (eg, ensuring that equivalent amounts of sarcolemmal proteins are loaded in each track, the transfer of large proteins is effi cient, and development of the signal in the linear range). In view of the highly localised delivery of AVI-4658, we chose an immunohistochemistry-based method to quantify dystrophin in specifi c myofi bres. This method has several advantages over other techniques, such as western blot and real-time RT-PCR, because it enables the in situ visualisation of the correct localisation of the expressed protein. Additionally, western blot and RT-PCR are not relevant for proteins that are only expressed in a subset of fi bres, which is the case here because of the local injection.
The quantitative immunohistochemistry method we used goes a step further than the one used in a recent exon-skipping study, 20 because fi bres are randomly selected to calculate the mean expression in the treated muscle and compared with that in the control muscle (fi gure 4). We extended our analysis by measuring the intensity of selected dystrophin-positive and dystrophinnegative fi bres within the same areas of the treated muscles. We show that the fl uorescent intensity of the dystrophin-positive fi bres was 42% of that of fi bres in healthy, non-dystrophic control muscles (fi gure 4).
In a recent clinical trial in which exon 51 was targeted, the investigators showed dystrophin expression in the tibialis anterior muscle after one injection of PRO051, a 2ĽO-methyl antisense oligonucleotide. 20 Although PRO051 and AVI-4658 target the same region of exon 51, we used a phosphorodiamidate morpholino oligomer chemistry, used a longer splice-skipping oligonuceotide, and treated a small intrinsic and relatively non-functional foot muscle, which enabled us to obtain bilateral muscle biopsies that were not available in the PRO051 study. Because staining with the MANDYS106 antibody, which was used in both studies, results in low-level labelling in some patients with DMD (fi gure 4), negative controls are crucial for accurate quantifi cation of the protein. This low-level labelling of dystrophin is absent only in patients with DMD in whom the MANDYS106 epitope (coded in exon 43) is deleted (data not shown), implying that a genuine product of DMD is detected by this high-affi nity antibody. Our controlled study of exon skipping for DMD clearly shows an increase in the expression of dystrophin in drug-treated muscles compared with the saline-injected contralateral muscle. Because a negative saline-injected control was not included in the previous study, 20 and the background concentration of endogenous dystrophin expression was not taken into account, the relative effi cacy of the two compounds for inducing dystrophin-positive fi bres cannot be compared directly. If we estimate that we obtained an average dystrophin intensity value of 26·4% (range 22·0-32·0%) in a much larger biopsy (about 0·5×2×2 cm; webappendix) compared with the 27% (range 17-35%) in the previous study, which reported biopsy sizes between 120-726 fi bres, 20 this might suggest that the phosphorodiamidate morpholino oligomer AVI-4658 compares favourably with the 2Ľ O-methyl chemistry. 20 This seems to be particularly relevant because the method used to measure intensity values in the PRO051 study averaged the intensities of the whole image and did not subtract the low-level background expression. However the methods for quantifying immunocytochemistry in the two studies are not identical, diff erent muscles were studied, and the volume of the injected drug was diff erent; therefore, direct comparison between the two studies cannot be made with precision. This implies that, in terms of the diff erent chemistries used for the antisense oligonucleotides, the effi cacies of the results of these two studies cannot be directly compared. Although PMOs that were designed to skip exon 23 were more effi cient than were 2ĽO-methyl oligomers after intramuscular injection in mdx mice, 22, 24 any diff erences in length among the antisense oligonucleotides might contribute to their effi cacy. 24 Nevertheless, both studies reported unequivocal expression of dystrophin at similar concentrations.
Whether this expression of dystrophin resulted in improved muscle function was not studied. However, in-frame deletions of the exons 48-51, 50-51, and 45-51 in DMD, which will lead to dystrophin that is similar to that induced in this study, have been described in multi-generation families in which the aff ected members were asymptomatic. 9, 10 We therefore anticipate that the dystrophin produced by the patients in our study would be functional and speculate that the missing domain is not essential for protein function or structure. The concentration of dystrophin needed to improve or preclude clinical symptoms will probably depend on the quantity and quality (molecular structure) of the protein. We recently reported that dystrophin expression of 27% of the concentration in healthy muscle was suffi cient to avoid skeletal muscle symptoms, 42 but the concentration of truncated dystrophin without exon 51 that is suffi cient to provide a clinical benefi t is not known. Nevertheless, if the increases in dystrophin concentration that we observed along the needle track were achieved after systemic delivery, then this might lead to a clinically signifi cant response. Preclinical studies in mdx mice have shown that seven weekly doses of PMOs resulted in a high number of dystrophin-positive fi bres, varying between 10% and 70% of the muscle fi bres in the diff erent muscles analysed. 17 Translation of dose from intramuscular to systemic studies or studies with the same delivery route but in diff erent species is diffi cult. However, in a recent study 18 in which dogs with canine X-linked muscular dystrophy were given an intravenous cocktail of morpholinos designed to skip exons 6 and 8 of dystrophin, expression of the protein was successfully restored and a clinical benefi t was noticed without adverse reactions to the high-doses of morpholinos used. This bodes well for systemic studies in humans. On the basis of these observations, we have initiated a dose-ranging study in ambulant patients with DMD to assess the safety and effi cacy of repeated doses of systemic intravenous AVI-4658 (ClinicalTrials.gov, number NCT00844597).
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